Detalles de la búsqueda
1.
Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience.
Ann Hematol
; 103(1): 321-334, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37971549
2.
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
Haematologica
; 108(1): 110-121, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35770532
3.
Sequence matters: Total body irradiation (TBI)-based myeloablative conditioning with post-transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBI.
Eur J Haematol
; 111(1): 146-153, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37058419
4.
Ocular involvement in patients with primary central-nervous-system lymphoma: Analysis of a multicentre study in Spain.
Br J Haematol
; 197(6): 792-795, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35307813
5.
Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy.
Hemasphere
; 8(5): e62, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38774657
6.
Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature.
Transplant Cell Ther
; 29(7): 473.e1-473.e6, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37086849
7.
High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion.
Cancer Gene Ther
; 30(1): 51-61, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36031661
8.
Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study.
BMJ Open
; 13(7): e071371, 2023 07 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37491085
9.
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Bone Marrow Transplant
; 58(6): 673-679, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36918682
10.
CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure.
Front Immunol
; 13: 904497, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35874685
11.
Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges.
Transplant Cell Ther
; 28(1): 43.e1-43.e5, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34757054
12.
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma.
Cancer Med
; 10(10): 3214-3223, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33932100
13.
The novel agonistic iNKT-cell antibody NKT14m induces a therapeutic antitumor response against B-cell lymphoma.
Oncoimmunology
; 8(2): e1546543, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30713807
14.
Correction to: High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion.
Cancer Gene Ther
; 30(1): 219, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36460806
15.
Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Bone Marrow Transplant
; 58(6): 738, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37076611
Resultados
1 -
15
de 15
1
Próxima >
>>